AUTL Stock Analysis: Buy, Sell, or Hold?
AUTL - Autolus Therapeutics plc American Depositary Share
$1.48
-0.13 (-8.07%)
▼
5d:
-9.2%
30d:
+0.0%
90d:
-0.67%
HOLD
LOW Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 11, 2026
27d
Get Alerted When AUTL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: AUTL shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: AUTL shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: AUTL is currently trading at $1.48, which is considered oversold relative to its 30-day fair value range of $1.50 to $1.64.
Technical Outlook: Technically, AUTL is showing sideways momentum. The price is currently testing key support at $1.48. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.1% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $8.55 (+477.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, AUTL is showing sideways momentum. The price is currently testing key support at $1.48. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.1% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $8.55 (+477.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.50 -
$1.64
Company Quality Score
43/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-8.1%)
- BULLISH: Trading 477.7% below Wall St target ($8.55)
- CAUTION: Recommendation downgraded due to -9.2% 5-day decline
Trading Range Analysis
30-Day Trading Range
$1.50 -
$1.64
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.48
Resistance Level
$1.75
Current Trend
Sideways
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.46
Wall Street Target
$8.55
(+477.7%)
Revenue Growth (YoY)
83655.2%
Share & Embed Analysis
Last updated: July 14, 2026 3:06 AM ET
Data refreshes hourly during market hours. Next update: 4:06 AM
Data refreshes hourly during market hours. Next update: 4:06 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AUTL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$413 | 54 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 54 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$122 | 55 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 59 HOLD |
